How Lilly plans to spend its GLP-1 money, and more from #ASH Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 9 December, 2025

See What’s Ahead—Download the 2026 Market Access Trends Report sponsored by Cencora

presented by Pra­tia ac­cel­er­ates U.S. ex­pan­sion with ma­jor­i­ty in­vest­ment in P1 Tri­als, strength­en­ing its glob­al ear­ly-phase on­col­o­gy net­work

news Pfizer to pay $150M upfront for small molecule GLP-1 from Fosun subsidiary BioNTech, BMS unwrap Phase 2 data for PD-L1xVEGF bispecific in breast cancer Lilly will be 'aggressive' in spending GLP-1 money, top dealmaker Van Naarden says Eli Lilly's Jaypirca makes first-line case in chronic lymphocytic leukemia, but ceiling may be capped Novartis says antibody helps prolong control of rare blood disorder

Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 16 11:30am ET Ensure EU GMP Annex I compliance while maintaining sterile injectable manufacturing excellence & agility sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

This week: Our latest survey captured the bleakest biotech outlook in a decade — but is recent momentum real or a mirage? Join us to hear what CEOs are saying about the industry’s direction. Sign up now.

endpoints pharma Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia? FDA sets higher bar for CAR-T cancer treatments, saying new entrants may need to prove superiority GSK walks away from remaining Ideaya programs, formally ending partnership Biosecure makes annual defense bill, with less 'bite' for drugmakers Merck outbid three competitors in $9.2B acquisition of Cidara FDA misses PDUFA review deadline for Agios' thalassemia drug Apple Tree Partners scores legal win against alleged holdout Russian investor

in case you missed it 1. Kymera's Dupixent-in-a-pill impresses in closely-watched early eczema readout 2. Updated: Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results •  Updated: Wave Life Sciences’ RNA obesity shot cuts fat and retains muscle, but appears to lag behind Lilly’s for now 3. Dyne says Duchenne drug succeeds in pivotal study, heads to FDA for approval 4.